Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.
Teipel, Stefan J; Dyrba, Martin; Ballarini, Tommasoet al.
2022 • In Journal of Alzheimer's Disease, 85 (3), p. 1267 - 1282
[en] [en] BACKGROUND: Inflammation has been described as a key pathogenic event in Alzheimer's disease (AD), downstream of amyloid and tau pathology. Preclinical and clinical data suggest that the cholinergic basal forebrain may moderate inflammatory response to different pathologies.
OBJECTIVE: To study the association of cholinergic basal forebrain volume and functional connectivity with measures of neuroinflammation in people from the AD spectrum.
METHODS: We studied 261 cases from the DELCODE cohort, including people with subjective cognitive decline, mild cognitive impairment, AD dementia, first degree relatives, and healthy controls. Using Bayesian ANCOVA, we tested associations of MRI indices of cholinergic basal forebrain volume and functional connectivity with cerebrospinal fluid (CSF) levels of sTREM2 as a marker of microglia activation, and serum levels of complement C3. Using Bayesian elastic net regression, we determined associations between basal forebrain measures and a large inflammation marker panel from CSF and serum.
RESULTS: We found anecdotal to moderate evidence in favor of the absence of an effect of basal forebrain volume and functional connectivity on CSF sTREM2 and serum C3 levels both in Aβ42/ptau-positive and negative cases. Bayesian elastic net regression identified several CSF and serum markers of inflammation that were associated with basal forebrain volume and functional connectivity. The effect sizes were moderate to small.
CONCLUSION: Our data-driven analyses generate the hypothesis that cholinergic basal forebrain may be involved in the neuroinflammation response to Aβ42 and phospho-tau pathology in people from the AD spectrum. This hypothesis needs to be tested in independent samples.
Disciplines :
Neurology
Author, co-author :
Teipel, Stefan J; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany
Dyrba, Martin; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
Ballarini, Tommaso; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Brosseron, Frederic; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
Bruno, Davide; School of Psychology, Liverpool John Moores University, Liverpool, UK
Buerger, Katharina; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig Maximilian University, Munich, Germany
Cosma, Nicoleta-Carmen; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Dechent, Peter; Department of Cognitive Neurology, MR-Research in Neurosciences, Georg-August-University, Goettingen, Germany
Dobisch, Laura; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Düzel, Emrah; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany
Ewers, Michael; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig Maximilian University, Munich, Germany
Fliessbach, Klaus; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
Haynes, John D; Bernstein Center for Computational Neuroscience, Berlin, Germany
Janowitz, Daniel; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig Maximilian University, Munich, Germany
Kilimann, Ingo; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany
Laske, Christoph; German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany ; Section for Dementia Research, Hertie Institute for Clinical Brain Research, Tuebingen, Germany ; Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany
Maier, Franziska; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany
Metzger, Coraline D; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany ; Department of Psychiatry and Psychotherapy, Otto-von-Guericke University, Magdeburg, Germany
Munk, Matthias H; German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany ; Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany ; Department of Biology, Systems Neurophysiology, Darmstadt University of Technology, Darmstadt, Germany
Peters, Oliver; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany ; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
Pomara, Nunzio; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA ; Department of Psychiatry, School of Medicine, New York University, New York City, NY, USA
Preis, Lukas; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Priller, Josef; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany ; Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Ramírez, Alfredo; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany ; Department of Psychiatry and Psychotherapy, Division of Neurogenetics and Molecular Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany ; Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA ; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
Roy, Nina; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Scheffler, Klaus; Department for Biomedical Magnetic Resonance, University of Tuebingen, Tuebingen, Germany
Schneider, Anja; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
Schott, Björn H; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany ; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany ; Leibniz Institute for Neurobiology, Magdeburg, Germany
Spottke, Annika; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurology, University Hospital Bonn, Bonn, Germany
Spruth, Eike J; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany
Wagner, Michael; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
Wiltfang, Jens; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany ; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany ; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Jessen, Frank; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany ; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
HENEKA, Michael ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany
Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.
Ewers M, Franzmeier N, Suarez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, Trojanowski JQ, ShawLM, WeinerMW, Haass C, Alzheimer's Disease Neuroimaging Initiative (2019) Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med 11, eaav6221.
McGeer PL, McGeer EG (2013) The amyloid cascadeinflammatory hypothesis of Alzheimer disease: Implications for therapy. Acta Neuropathol 126, 479-497.
Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement 12, 719-732.
Cai Z, Hussain MD, Yan LJ (2014) Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci 124, 307-321.
Bartus RT, Dean RL, 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89, 337-343.
Lehner KR, Silverman HA, Addorisio ME, Roy A, Al-Onaizi MA, Levine Y, Olofsson PS, Chavan SS, Gros R, Nathanson NM, Al-Abed Y, Metz CN, Prado VF, Prado MAM, Tracey KJ, Pavlov VA (2019) Forebrain cholinergic signaling regulates innate immune responses and inflammation. Front Immunol 10, 585.
YangY, PengY, Yang J (2018) Galantamine protects against hydrochloric acid aspiration-induced acute respiratory distress syndrome in rabbits. Trop J Pharm Res 17, 669-673.
Schmitz TW, Soreq H, Poirier J, Spreng RN (2020) Longitudinal basal forebrain degeneration interacts with TREM2/C3 biomarkers of inflammation in presymptomatic Alzheimer's disease. J Neurosci 40, 1931-1942.
Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, Fliessbach K, Franke C, Fuentes M, Heneka MT, Janowitz D, Kilimann I, Laske C, Menne F, Nestor P, Peters O, Priller J, Pross V, Ramirez A, Schneider A, Speck O, Spruth EJ, Teipel S, Vukovich R, Westerteicher C, Wiltfang J, Wolfsgruber S, Wagner M, Duzel E (2018) Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimers Res Ther 10, 15.
Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro E, Jr., Dos Santos GA, da Silva RE, Mitchell AJ, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Kloppel S, Teipel SJ (2014) Subregional basal forebrain atrophy in Alzheimer's disease: A multicenter study. J Alzheimers Dis 40, 687-700.
Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stockel S, Dietrich O, Reiser MF, Moller HJ, Hampel H (2005) Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 128, 2626-2644.
Fritz HJ, Ray N, Dyrba M, Sorg C, Teipel S, Grothe MJ (2019) The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. Hum Brain Mapp 40, 868-878.
Chiesa PA, Cavedo E, Grothe MJ, Houot M, Teipel SJ, Potier MC, Habert MO, Lista S, Dubois B, Hampel H, INSIGHT-preAD Study Group and the Alzheimer Precision Medicine Initiative (APMI) 1 (2019) Relationship between basal forebrain resting-state functional connectivity and brain amyloid-beta deposition in cognitively intact older adults with subjective memory complaints. Radiology 290, 167-176.
Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. J R Stat Soc Series B Stat Methodol 67, 301-320.
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M, Subjective Cognitive Decline Initiative Working Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10, 844-852.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, PhelpsCH(2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ (2017) Unbiased estimates of cerebrospinal fluid betaamyloid 1-42 cutoffs in a large memory clinic population. Alzheimers Res Ther 9, 8.
Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wullner U, Svenningsson P, Sanchez-Valle R, Molinuevo JL, Corvol JC, Heneka MT, AETIONOMYstudy group (2020) Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimers Dement 16, 292-304.
Kurth F, Gaser C, Luders E (2015) A 12-step user guide for analyzing voxel-wise gray matter asymmetries in statistical parametric mapping (SPM). Nat Protoc 10, 293-304.
Chao-GanY, Yu-FengZ(2010)DPARSF: AMATLABtoolbox for "pipeline" data analysis of resting-state fMRI. Front Syst Neurosci 4, 13.
Franzmeier N, Caballero MAA, Taylor ANW, Simon-Vermot L, Buerger K, Ertl-Wagner B, Mueller C, Catak C, Janowitz D, Baykara E, Gesierich B, Duering M, Ewers M, Alzheimer's Disease Neuroimaging Initiative (2017) Resting-state global functional connectivity as a biomarker of cognitive reserve in mild cognitive impairment. Brain Imaging Behav 11, 368-382.
Goodman S (2008) A dirty dozen: Twelve P-value misconceptions. Semin Hematol 45, 135-140.
Wagenmakers EJ, Marsman M, Jamil T, Ly A, Verhagen J, Love J, Selker R, Gronau QF, Smira M, Epskamp S, MatzkeD, Rouder JN, MoreyRD(2018) Bayesian inference for psychology. Part I: Theoretical advantages and practical ramifications. Psychon Bull Rev 25, 35-57.
Tibshirani R (1996) Regression shrinkage and selection via the Lasso. J R Stat Soc Series B Methodol 58, 267-288.
Li Q, Lin N (2010) The Bayesian elastic net. Bayesian Anal 5, 151-170.
van Erp S, Oberski DL, Mulder J (2019) Shrinkage priors for Bayesian regularized regression. J Math Psychol 89, 31-50.
Hastie T, Tibshirani R, Wainwright M (2015) Statistical learning with sparsity: The Lasso and generalizations, Chapman and Hall/CRC, Boca Raton, FL.
Kruschke JK (2015) Doing Bayesian Data Analysis-A Tutorial with R, JAGS, and Stan, Elsevier, San Diego, CA.
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Muller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Erturk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C (2019) Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci 22, 191-204.
Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner S, Gildehaus FJ, Ozmen L, Suarez-Calvet M, Bartenstein P, Baumann K, Ewers M, Herms J, Haass C, Rominger A (2017) Increase of TREM2 during aging of an Alzheimer's disease mouse model is paralleled by microglial activation and amyloidosis. Front Aging Neurosci 9, 8.
Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM (1992) Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease. Res Immunol 143, 617-620.
Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, Stevens B, Lemere CA (2017) Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med 9, eaaf6295.
Xu Z, Shen X, Pan W, Alzheimer's Disease Neuroimaging Initiative (2014) Longitudinal analysis is more powerful than cross-sectional analysis in detecting genetic association with neuroimaging phenotypes. PLoS One 9, e102312.
Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB (2016) Cerebrospinal fluid markers of Alzheimer's disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer's disease. J Alzheimers Dis 50, 873-886.
Papenberg G, Ferencz B, Mangialasche F, Mecocci P, Cecchetti R, Kalpouzos G, Fratiglioni L, Backman L (2016) Physical activity and inflammation: Effects on gray-matter volume and cognitive decline in aging. Hum Brain Mapp 37, 3462-3473.
Schipke CG, Menne F, Rubow S, Sigle JP, Peters O, Grimmer T (2020) Value of a panel of 6 serum biomarkers to differentiate between healthy controls and mild cognitive impairment due to Alzheimer disease. Alzheimer Dis Assoc Disord 34, 318-324.
Malaguarnera L, Motta M, Di Rosa M, Anzaldi M, Malaguarnera M (2006) Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. Neuropathology 26, 307-312.
Lindberg C, Chromek M, Ahrengart L, Brauner A, Schultzberg M, Garlind A (2005) Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochem Int 46, 551-557.
Heneka MT, McManus RM, Latz E (2018) Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 19, 610-621.
Hanslik KL, UllandTK(2020) The role of microglia and the Nlrp3 inflammasome in Alzheimer's disease. Front Neurol 11, 570711.
Yap JKY, Pickard BS, Chan EWL, Gan SY (2019) The role of neuronal NLRP1 inflammasome in Alzheimer's disease: Bringing neurons into the neuroinflammation game. Mol Neurobiol 56, 7741-7753.
Ke P, Shao BZ, Xu ZQ, Chen XW, Wei W, Liu C (2017) Activating alpha7 nicotinic acetylcholine receptor inhibits NLRP3 inflammasome through regulation of beta-arrestin-1. CNS Neurosci Ther 23, 875-884.
Falcon C, Monte-Rubio GC, Grau-Rivera O, Suarez-Calvet M, Sanchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL (2019) CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. Neuroimage Clin 23, 101801.
Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA (2010) In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 7, 34.
Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM (2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912.
Yang G, Meng Y, Li W, Yong Y, Fan Z, Ding H, Wei Y, Luo J, Ke ZJ (2011) Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism. Brain Pathol 21, 279-297.
Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T (2005) Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol 166, 1475-1485.
Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gisladottir B, Wettergreen M, Torsetnes SB, Grontvedt GR, Waterloo KK, Aarsland D, Nilsson LNG, Fladby T (2019) Glial activation and inflammation along the Alzheimer's disease continuum. J Neuroinflammation 16, 46.
Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 21, 9-15.
Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, HanssonO(2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 7, e30525.
Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, Zhang C, Yu JT (2019) Inflammatory markers in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry 90, 590-598.
Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Jr., Brachova L, Yan SD, Walker DG, Shen Y, Rogers J (2001) Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35, 72-79.
Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, Tosun D, Weiner M, Alzheimer's Disease Neuroimaging Initiative (2013) CSF protein biomarkers predicting longitudinal reduction of CSF beta-amyloid42 in cognitively healthy elders. Transl Psychiatry 3, e293.
Herdick M, Dyrba M, Fritz HJ, Altenstein S, Ballarini T, Brosseron F, Buerger K, Can Cetindag A, Dechent P, Dobisch L, Duezel E, Ertl-Wagner B, Fliessbach K, Dawn Freiesleben S, Frommann I, Glanz W, Dylan Haynes J, Heneka MT, Janowitz D, Kilimann I, Laske C, Metzger CD, Munk MH, Peters O, Priller J, Roy N, Scheffler K, Schneider A, Spottke A, Jakob Spruth E, Tscheuschler M, Vukovich R, Wiltfang J, Jessen F, Teipel S, Grothe MJ (2020) Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. Neuroimage Clin 28, 102495.
Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, Mariani C, Bresolin N, Scarpini E (2007) IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. Eur J Neurol 14, e3-4.
Elahi FM, Casaletto KB, La Joie R, Walters SM, Harvey D, Wolf A, Edwards L, Rivera-Contreras W, Karydas A, Cobigo Y, Rosen HJ, DeCarli C, Miller BL, Rabinovici GD, Kramer JH (2020) Plasma biomarkers of astrocytic and neuronal dysfunction in early-and late-onset Alzheimer's disease. Alzheimers Dement 16, 681-695.
Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM, Anderson AM, Tyor WR (2019) CSF cytokines in aging, multiple sclerosis, and dementia. Front Immunol 10, 480.
Calandra T, Bucala R (2017) Macrophage migration inhibitory factor (MIF): A glucocorticoid counter-regulator within the immune system. Crit Rev Immunol 37, 359-370.
Petralia MC, Battaglia G, Bruno V, Pennisi M, Mangano K, Lombardo SD, Fagone P, Cavalli E, Saraceno A, Nicoletti F, Basile MS (2020) The role of macrophage migration inhibitory factor in Alzheimer's disease: Conventionally pathogenetic or unconventionally protective? Molecules 25, 291.
